New antibody combo shows promise for tough childhood cancer
NCT ID NCT03363373
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs—naxitamab (an antibody) and GM-CSF (an immune booster)—in children and adults with high-risk neuroblastoma that has not responded well to previous treatments. The goal is to see if this therapy can shrink or eliminate tumors in the bone and bone marrow. Participants receive treatment for up to 101 weeks and are followed for five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Naxitamab (a lab-made antibody) and GM-CSF (a protein that boosts immune cells)
What this could lead to
If successful, this could offer a new treatment option for patients with high-risk neuroblastoma that has not responded to standard therapy.
What could go wrong
This is a phase 2 trial with 122 participants, so results are still preliminary. The treatment may cause side effects, and not all patients may respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milan, 20133, Italy
-
Giannina Gaslini Hospital
Genoa, Genoa, 16147, Italy
-
Hong Kong Children's Hospital
Hong Kong, Hong Kong
-
Hospital Infantil Universitario Niño Jesús
Madrid, 28009, Spain
-
Hospital Sant Joan de Déu
Barcelona, 08950, Spain
-
Hospital Universitario Virgen Del Rocío
Seville, Spain
-
Hospital Universitario y Politécnico La Fe
Valencia, 46026, Spain
-
Johannes Gutenberg-Universität
Mainz, Germany
-
Leeds General Infirmary
Leeds, LS1 3EX, United Kingdom
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Ospedale Pediatrico Bambino Gesù
Rome, Italy
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Tata Memorial Centre
Mumbai, 400012, India
-
The Hospital for Sick Children
Toronto, M5G 1X8, Canada
-
The Royal Glasgow Children's Hospital
Glasgow, G51 4TF, United Kingdom
-
University Hospital Regensburg
Regensburg, Germany
-
University Hospital Southampton
Southampton, SO16 6YD, United Kingdom
-
University Medical Center Hamburg-Eppendorf
Hamburg, Germany